Sunesis Pharmaceuticals (FRA:RYIS) FCF Margin % : 0.00% (As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sunesis Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2020 was €-4.66 Mil. Sunesis Pharmaceuticals's Revenue for the three months ended in Dec. 2020 was €0.00 Mil. Therefore, Sunesis Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2020 was 0.00%.

As of today, Sunesis Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for Sunesis Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:RYIS' s FCF Margin % Range Over the Past 10 Years
Min: -17060.55 Med: 0 Max: 0
Current: -17060.55

FRA:RYIS's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -141.21 vs FRA:RYIS: -17060.55

Sunesis Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Sunesis Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals FCF Margin % Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

FCF Margin %

Get a 7-Day Free Trial

-1,457.57

-5,409.20

-10,312.98

-1,070.04

-17,801.01

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
FCF Margin %	Get a 7-Day Free Trial															-180.76	-4,768.81	-	-	-

Competitive Comparison of Sunesis Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Sunesis Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunesis Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's FCF Margin % falls into.

Sunesis Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sunesis Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2020 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2020 )	/	Revenue (A: Dec. 2020 )
	=	-17.623	/	0.099
	=	-17,801.01 %

Sunesis Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2020 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2020 )	/	Revenue (Q: Dec. 2020 )
	=	-4.655	/	0
	=	%

Sunesis Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines